GMDA
Gamida Cell Ltd.
A biopharmaceutical company in Jerusalem that makes cell therapies for people with blood cancers. Its flagship product, Omisirge, is an FDA-approved therapy grown from umbilical cord blood, using a technology that multiplies stem cells with nicotinamide — a form of vitamin B3. Founded in 1998 by a scientist from Hadassah University Hospital, the company grew out of his research on how stem cells develop.
CINS: M47364100HealthcareIL1 holder
Total Value
$54
Total Shares
1.5K
Net Share Change
-2.14M
Activity
1 selling
Investor
Value
Shares
Weight
Change
